170 related articles for article (PubMed ID: 19922468)
1. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
Okamoto I
FEBS J; 2010 Jan; 277(2):309-15. PubMed ID: 19922468
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
Mitsudomi T; Yatabe Y
FEBS J; 2010 Jan; 277(2):301-8. PubMed ID: 19922469
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
[TBL] [Abstract][Full Text] [Related]
6. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K
J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026
[TBL] [Abstract][Full Text] [Related]
7. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
Takeuchi K; Ito F
FEBS J; 2010 Jan; 277(2):316-26. PubMed ID: 19922467
[TBL] [Abstract][Full Text] [Related]
8. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Malapelle U; Bellevicine C; Zeppa P; Palombini L; Troncone G
Diagn Cytopathol; 2011 Sep; 39(9):703-10. PubMed ID: 21837660
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted therapy.
Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor targeted therapies for solid tumours.
Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
13. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
14. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
Govindan R
J Clin Oncol; 2010 Feb; 28(5):713-5. PubMed ID: 20038722
[No Abstract] [Full Text] [Related]
15. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
16. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
17. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
19. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
20. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]